Physician profile
Michael E Dant
NPI 1518944081
$4,449.61
in general payments reported to CMS, 2019-2025
36 companies · $740 in 2025
The $740 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $529 · 2021: $1,067 · 2022: $442 · 2023: $584 · 2024: $617 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,941.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $797.37 | 2020-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $533.75 | 2019-2025 | |
| Astellas Pharma US INC | $415.22 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $355.94 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $305.21 | 2019-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $282.60 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $180.29 | 2021-2024 | Camzyos, Eliquis |
| Dexcom, INC. | $177.06 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $174.54 | 2019-2024 | |
| Amgen INC. | $170.35 | 2020-2025 | Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $157.50 | 2021 | |
| Supernus Pharmaceuticals, INC. | $106.80 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $98.41 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $83.95 | 2019-2024 | Breztri |
| Heartflow, INC. | $78.45 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $70.10 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $61.14 | 2019-2021 | |
| Allergan, INC. | $36.78 | 2019 | |
| Medtronic, INC. | $35.14 | 2023-2025 | Inceptiv, Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $34.94 | 2022-2023 | |
| Boston Scientific Corporation | $31.79 | 2021 | |
| Jazz Pharmaceuticals INC. | $23.97 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $23.18 | 2022 | |
| Sunovion Pharmaceuticals INC. | $21.14 | 2021 | |
| Upsher-Smith Laboratories LLC | $19.84 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.63 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.14 | 2025 | Caplyta |
| Mylan Specialty L.P. | $17.96 | 2020 | |
| Paratek Pharmaceuticals, INC. | $17.64 | 2020 | |
| Merck Sharp & Dohme LLC | $16.86 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.12 | 2020 | |
| Daiichi Sankyo INC. | $14.49 | 2023 | Injectafer |
| Xeris Pharmaceuticals, INC. | $14.46 | 2020 | |
| Irhythm Technologies, INC. | $14.16 | 2022 | |
| Genentech USA, INC. | $14.10 | 2020 | |
| Smith+Nephew, INC. | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.